<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46B41008-0EB4-4E28-BBFB-E98366999EC5"><gtr:id>46B41008-0EB4-4E28-BBFB-E98366999EC5</gtr:id><gtr:name>Durham University</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Old Shire Hall</gtr:line1><gtr:line2>Old Elvet</gtr:line2><gtr:line4>Durham</gtr:line4><gtr:line5>County Durham</gtr:line5><gtr:postCode>DH1 3HP</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46B41008-0EB4-4E28-BBFB-E98366999EC5"><gtr:id>46B41008-0EB4-4E28-BBFB-E98366999EC5</gtr:id><gtr:name>Durham University</gtr:name><gtr:address><gtr:line1>Old Shire Hall</gtr:line1><gtr:line2>Old Elvet</gtr:line2><gtr:line4>Durham</gtr:line4><gtr:line5>County Durham</gtr:line5><gtr:postCode>DH1 3HP</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DE38C546-670D-43A2-9DDC-B7C33D7F62AA"><gtr:id>DE38C546-670D-43A2-9DDC-B7C33D7F62AA</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Parker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FE000533%2F1"><gtr:id>E4F19D1B-4587-43FB-98DB-BB785215FEDF</gtr:id><gtr:title>FLIC - Functional Ligands for Imaging in Cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/E000533/1</gtr:grantReference><gtr:abstractText>Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) are two essential imaging methods whose clinical application in cancer research is well established. Recent advances in clinical instrumentation have resulted in equipment with improved resolution and sensitivity. However, current contrast or imaging agents for use in MRI and PET are not as effective for the 21st century instrumentation now being deployed. The design, synthesis and validation of improved, new functional imaging probes is urgently needed. To develop such probes for cancer a multidisciplinary team is required with expertise in synthetic chemistry and radiochemistry, pre-clinical and clinical imaging sciences, and cancer drug development, working in harmony with the needs and aspirations of cancer biology. No single grouping in the UK can currently offer this range of expertise, and therefore to make progress in this important area the formation of a multi-centre collaborative grouping is essential. The proposed FLIC platform grant will establish a collaborative team with strengths in chemistry, cancer imaging and drug development, and in so doing create a chemistry-life science interface that will address a key need in personalised medicine, producing new chemical entities with genuine utility for healthcare and amenable to commercial exploitation.</gtr:abstractText><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2006-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>216231</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>427683</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research Campaign</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Cancer Research Campaign</gtr:fundingOrg><gtr:fundingRef>Progamme grant</gtr:fundingRef><gtr:id>993149C3-6CF6-435C-A831-2FFA03FEB5BA</gtr:id><gtr:outcomeId>5eba3eb85eba3ed6</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>427683</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research Campaign</gtr:description><gtr:fundingOrg>Cancer Research Campaign</gtr:fundingOrg><gtr:fundingRef>Progamme grant</gtr:fundingRef><gtr:id>A1CCAFC1-4CC9-4CD2-B266-70798E324619</gtr:id><gtr:outcomeId>r-5520881121.531950684204c</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>How to make probes for use as contrast agents in MRI more effective at clinically relevant fields.</gtr:description><gtr:exploitationPathways>In developing new probes for MRI</gtr:exploitationPathways><gtr:id>D653D127-EC18-4E59-8CBB-26D0A0489E0E</gtr:id><gtr:outcomeId>54536ef2b21766.05228970</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B360950A-19FD-40D3-B881-AB31D83E0A2B</gtr:id><gtr:title>Synthesis, stereocontrol and structural studies of highly luminescent chiral tris-amidepyridyl-triazacyclononane lanthanide complexes.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80e4b3621b956f0017a38c4752c655dc"><gtr:id>80e4b3621b956f0017a38c4752c655dc</gtr:id><gtr:otherNames>Neil ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>544516be6765d1.19758526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA527CDC-9CA1-4EA6-8034-4FC55A990702</gtr:id><gtr:title>Strategies to enhance signal intensity with paramagnetic fluorine-labelled lanthanide complexes as probes for 19-F magnetic resonance,</gtr:title><gtr:parentPublicationTitle>Dalton Transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38d1e94652f26c4bb4ec76e3d1d319ae"><gtr:id>38d1e94652f26c4bb4ec76e3d1d319ae</gtr:id><gtr:otherNames>n/a n/a (Final Report data)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>r_7747210319035994c6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D116E3BC-A379-42F2-A018-4D7B60D1315E</gtr:id><gtr:title>Variation of water exchange dynamics with ligand structure and stereochemistry in lanthanide complexes based on 1,4-diazepine derivatives.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2bfe52e74d33a8d68e4243bde1c0e9f"><gtr:id>c2bfe52e74d33a8d68e4243bde1c0e9f</gtr:id><gtr:otherNames>Elemento EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>doi_53d02b02b3fbd765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD79B235-6EF3-4783-8C74-DABAD7FFF863</gtr:id><gtr:title>Design principles and theory of paramagnetic fluorine-labelled lanthanide complexes as probes for (19)F magnetic resonance: a proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/470904b70b5da14c4b918058a2920d6b"><gtr:id>470904b70b5da14c4b918058a2920d6b</gtr:id><gtr:otherNames>Chalmers KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn><gtr:outcomeId>doi_53cfc2fc2c959a28</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0385B3ED-E699-4F42-989B-78AE20E84A62</gtr:id><gtr:title>Characterisation and evaluation of paramagnetic fluorine labelled glycol chitosan conjugates for (19)F and (1)H magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bb4dd889381e6d03613744fb80dd629"><gtr:id>8bb4dd889381e6d03613744fb80dd629</gtr:id><gtr:otherNames>De Luca E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0949-8257</gtr:issn><gtr:outcomeId>54450fd4b77c27.54170976</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/E000533/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>E48C802F-8897-4353-910A-09D09331BB82</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical science &amp; disease</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>